Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

42.08 -1.02 (-2.37%)
Streaming Delayed Price Updated: 1:11 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
Shares soared and then tumbled Friday after the company offered $275 million in public shares. 
Via Investor's Business Daily
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Analyst Expectations for Kymera Therapeutics's Future
Via Benzinga
Preview: Kymera Therapeutics's Earnings
Via Benzinga
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Proposed Public Offering
From Kymera Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Kymera Therapeutics
Via Benzinga
Expert Ratings for Kymera Therapeutics
Via Benzinga
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Company to provide update on its emerging pipeline of high-value immunology programs 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
From Kymera Therapeutics, Inc.
Via GlobeNewswire
More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades. 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know
Via Benzinga
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Why Shares of Kymera Therapeutics Jumped on Tuesday
The company had a big bounce after hitting a 52-week low the day before. 
Via The Motley Fool
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to... 
Via Benzinga
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.